Prediction of pathological complete response and prognosis in locally advanced rectal cancer

Table 1 Characteristics of patients with or without pathologic complete response

Factors	n (%)
Gender
Male	97 (75.8)
Female	31 (24.2)
Age group (yr)
≤ 60	65 (50.8)
> 60	63 (49.2)
BMI (kg/m2)
< 18.5	9 (7.0)
18.5-23.9	64 (50.0)
≥ 24	55 (43.0)
cT stage
cT3	105 (82.0)
cT4	23 (18.0)
cN stage
cN0	11 (8.6)
cN+	117 (91.4)
Distance from the anal verge to rectal cancer (cm)
≤ 5	65 (51.6)
> 5	62 (48.4)
Tumor size (cm)
≤ 5.75	95 (74.2)
> 5.75	33 (25.8)
Tumor circumference proportion
≤ 1/2	18 (14.1)
> 1/2	110 (85.9)
Chemotherapy
XELOX	88 (68.8)
Capecitabine monotherapy	7 (5.5)
Others	33 (25.8)
Time interval (wk)
≤ 6	15 (11.7)
6-10	85 (66.4)
> 10	28 (21.9)
CEA (ng/mL)
≤ 5	73 (57.0)
> 5	55 (43.0)
CA199 (U/mL)
≤ 37	105 (82.0)
> 37	23 (18.0)
CA125 (U/mL)
≤ 35	124 (96.9)
> 35	4 (3.1)
CA153 (U/mL)
≤ 25	126 (98.4)
> 25	2 (1.6)
CA724 (U/mL)
≤ 8	118 (92.2)
> 8	10 (7.8)
NLR
≤ 3.05	92 (71.9)
> 3.05	36 (28.1)
PLR
≤ 117.08	46 (35.9)
> 117.08	82 (64.1)
LMR
≤ 2.73	24 (18.8)
> 2.73	104 (81.2)
SII
≤ 284.51	16 (12.5)
> 284.51	112 (87.5)
PIV
≤ 102.41	17 (13.3)
> 102.41	111 (86.7)
pCR
Yes	42 (32.8)
No	86 (67.2)

BMI: Body mass index; CEA: Carcinoembryonic antigen; NLR: Neutrophil to lymphocyte ratio; PLR: Platelet to lymphocyte ratio; LMR: Lymphocyte to monocyte ratio; SII: Systemic immune-inflammation index; PIV: Pan immune inflammation value; pCR: Pathologic complete response.